Good day, and thank you for standing by. Welcome to Zymeworks' first quarter 2023 results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Jack Spinks, Director of Investor Relations. Please go ahead. Good afternoon and welcome everyone. My name is Jack Spinks, Head of Investor Relations here at Zymeworks. Today, we'll discuss our first quarter financial results, as well as provide an update to our ongoing business. Before we begin, I'd like to remind you that we will be making a number of forward-looking statements during this call, including, without limitation, those forward-looking statements identified in our presentation slides and the accompanying oral commentary. Forward-looking statements are based upon our current expectations and various assumptions and are subject to the usual risks and uncertainties associated with companies in our industry and at our stage of development. For a discussion of these risks and uncertainties, we refer you to our latest SEC filings as found on our website and as filed with the SEC. Later in this call, Chris Astle, our Senior Vice President and Chief Financial Officer, will be discussing our financial results, including certain non-GAAP measures. Description of our non-GAAP measures and a reconciliation to the most directly comparable financial measures as determined in accordance with GAAP are described in detail in our press release, which is available on our website at www.zymeworks.com under the Investor Relations tab. As a reminder, the audio and slides from this call will also be available on the Zymeworks website later today. Now, I will turn the call over to Chris, our Senior Vice President and CFO. Chris? Thanks, Jack. Thank you everyone for joining us today for our first quarter 2023 earnings call. As a reminder, I'd like to note that while I'll be presenting the prepared remarks and participating in Q&A today, Kenneth Galbraith, our Chair and CEO, Neil Klompas, our President and COO, and Paul Moore, our CSO, will also be available for Q&A following this portion of the call. With that, I'd like to begin today's call with an overview of our financial results, followed by a few recent developments and noteworthy updates across our business before we open the lines for Q&A. This afternoon, Zymeworks reported financial results for the first quarter ended March 31st, 2023. Zymeworks' net loss for the quarter ended March 31st, 2023 was $24.4 million or $0.37 per diluted share compared to a net loss of $72.6 million for quarter ended March 31st, 2022. This decrease in net loss of approximately 66% year-over-year was driven largely by revenue from the reimbursable amounts received due to our collaboration agreement with Jazz and a decrease in R&D expenses. As reported, our revenue for the first quarter of 2023 was $35.6 million compared to $1.9 million for the same period in 2022. The increase in revenues were largely due to reimbursable amounts received for zanidatamab's clinical development and manufacturing pursuant to our collaboration and licensing agreement with Jazz and research support and other payments from partners. Research and development expense for the quarter ended March 31st, 2023 decreased by $16.6 million to $45.9 million as compared to $62.5 million for the quarter ended March 31st, 2022. This decrease of 27% from the prior year related primarily to lower CRO and manufacturing expenses related to zanidatamab development and lower headcount-related expenses due to a decrease in headcount as compared to the same period in 2022. These were offset partially by an increase in clinical investigator costs for zanidatamab and an increase in preclinical expenses for the continued development of our preclinical pipeline programs. As a reminder to those listening today, as announced on April 26, Zymeworks and Jazz entered into a transaction which, when closed, will transfer certain assets, contracts, and employees associated with the development of zanidatamab from Zymeworks to Jazz This transaction was contemplated in order to simplify, focus, and potentially expedite the clinical development and commercialization of zanidatamab. The financial terms, as previously disclosed under the original licensing and collaboration agreement, remain unchanged. Zymeworks will continue to be eligible for reimbursement of certain costs for activities where we maintain responsibility. Zymeworks is also eligible for reimbursement of certain prepayments to third parties for services or other expenses under contracts to be transferred to Jazz pursuant to the agreement. In connection with our entry into these agreements, we anticipate our future research and development expenses and corresponding reimbursement revenue relating to zanidatamab under the license agreement with Jazz to decrease significantly. This reflects the transfer of responsibility as contemplated under the agreement, where Jazz will directly bear the ongoing zanidatamab-related costs incurred following the closing, as opposed to the previously contemplated reimbursement mechanism. In connection with our amended agreement with Jazz, certain costs that we expect to incur will not be recovered by us, and the reimbursements to us from Jazz for the first quarter 2023 expenses will be reduced by the final agreed costs in connection with the transfer of the contracts and responsibilities to Jazz. We expect to begin recording the effect of these non-recoverable costs in future periods. We expect our working capital requirements relating to our agreements with Jazz will be significantly reduced in Q2 due to the transfer of prepaid expenses to Jazz and the reduction in the receivables from Jazz under the reimbursement mechanism. For the quarter ended March 31st, 2023, general and administrative expenses were $16.9 million compared to $12.1 million for the same period in 2022. Excluding the significant non-cash recovery of $5.1 million in stock-based compensation, but including the impacts of restructuring as recorded in the first quarter of 2022, our general and administrative expenses decreased by approximately $2 million year-over-year on a non-GAAP basis, in line with our expectations. Our cash resources consisting of cash equivalents, and marketable securities were $412.4 million as of March 31, 2023. As of May 8, 2023, we had approximately 66.7 million fully diluted shares outstanding. With the continued focus on the balance sheet and the significant transformative impacts of the non-dilutive inflows from our licensing and collaboration agreement, we continue to expect our cash resources to fund our planned operations through at least 2026 and potentially beyond. We are reiterating our net cash operating burn guidance of between $90 million and $120 million for the full year 2023. Neither of these guidance figures have changed from previous expectations as a result of the transfer of the ZZI entity to Jazz and amendment to the licensing and collaboration agreement with Jazz. For additional details on our quarterly results and for a description of our non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, I encourage you to review our earnings through the SEC filings as available on our website at www.zymeworks.com. I'd like to spend a few minutes talking about our early R&D portfolio, which we recently highlighted at AACR, as well as some brief updates to our clinical program. Last year was an important year for our early R&D programs as we unveiled 4 new preclinical candidates and multiple platform technologies that enable us to continue developing novel therapeutics. This year, we have continued that momentum with a significant presence at AACR, where we presented 11 posters showcasing the focused development program we have in the antibody drug conjugate or ADC and multispecific antibody therapeutics or MSAT space. While I will encourage you to listen to our AACR webcast that discusses these product candidates and technology platforms in detail, I would like to highlight that we expect to nominate this year an additional IND candidate slated for 2025 submission. We also continue to remain focused on utilizing partnerships as a means to both fund and expedite development of additional programs while leveraging additional non-dilutive funding mechanisms. Our partnership strategy is purposeful. With the 5x5 strategy we laid out in October of last year, which outlines our plan to have five new INDs by 2027, we believe we will have the opportunity and funding to bring five candidates to the clinic. Our robust technology platforms and world-class early R&D team provide us with the tools to continue growing our pipeline of early-stage preclinical product candidates beyond just these five in-house programs. These potential preclinical product candidates represent both a potential source of non-dilutive funding and also can act as a source of screening for opportunities that we believe will help create a portfolio of both in-house and partnered candidates. We anticipate that for the in-house candidates developed via our 5x5 strategy, we would progress candidates through phase II clinical studies, where we would then pursue an ex-U.S. partnering strategy. With that, I'll briefly touch on zanidatamab, our clinical candidate recently partnered with Jazz Pharmaceuticals in the fourth quarter of last year. As you may have seen, our partners, Jazz and BeiGene, recently announced two exciting upcoming presentations at ASCO in June of this year. The first I will speak to you today represents the first zanidatamab abstract to receive an oral presentation at a major medical meeting, where we intend to discuss the full findings from our phase II pivotal study of zanidatamab as monotherapy in previously treated HER2-amplified biliary tract cancer or BTC. Second line BTC has no FDA-approved HER2-targeted treatment options, and our top-line data, which showed a confirmed ORR of 41.3% and a median duration of response of 12.9 months in previously treated patients with HER2-amplified and expressing disease as presented in December of 2022, would represent a potentially significant step forward in the treatment of patients with previously treated HER2-amplified BTC. We look forward to the presentation of the full dataset by our partner, Jazz, in June at the 2023 ASCO annual meeting in Chicago. The second abstract accepted for a poster presentation at ASCO to be presented by our partner BeiGene will be an update to the previously presented results from the phase I b phase II study of zanidatamab in combination with docetaxel as a first-line therapy for patients with advanced HER2-positive breast cancer. Presented at ASCO 2022, this study provided a promising ORR of 90% in the study population. The future potential milestone and royalty payments from our zanidatamab licensing and collaboration agreement with Jazz, which will remain unchanged following our entry into the amended collaboration agreement and our similar agreement with BeiGene, are expected to continue to be a significant source of non-dilutive capital for Zymeworks as zanidatamab progresses towards potential approval, which would come with regulatory and commercial milestones. Along with our global partner, Jazz and Asia Pacific partner BeiGene, we look forward to the continued global development of zanidatamab, where we believe zanidatamab has the potential to treat a broad range of HER2 expressing cancers, including potential to address unmet need outside of our two pivotal studies in BTC and GEA. We continue to have an exciting calendar ahead of us over the coming two years. As I mentioned earlier, with the upcoming presentations at ASCO and additional potential publications over the coming months, our partners will continue to present zanidatamab data that we believe can help position it, if approved, as the HER2 targeted antibody of choice for patients with HER2 expressing cancers. Later this year, we also plan to present additional data from our weekly cohort of zanidatamab zovodotin or zani-zo, our HER2 targeted ADC, and expect to launch our two phase II studies in non-small cell lung cancer in combination with PD-1 and in breast cancer after progression on T-DXd and in patients with lower levels of HER2 expression. We continue to pursue a combination strategy and would expect to partner this asset prior to any registrational studies. While we need to gather more clinical data in the target indications, we believe that zani-zo has the potential to be a preferred HER2 targeted ADC after patients progress on T-DXd or where a combination approach with the use of an ADC may make sense. We look forward to the continued development of this asset and reporting on the continued progress. Moving on to our portfolio of preclinical assets. We expect to nominate the next preclinical product candidate this year with an IND filing plan for 2025. We also continue to expect 2024 IND filings for ZW191, our folate receptor alpha-targeting topoisomerase I ADC, and for ZW171, our mesothelin-targeting 2+1 T-cell engaging bispecific antibody. Further, we anticipate nominating a 2026 IND candidate in calendar year 2024 as well. This timeline highlights our commitment to our 5x5 strategy, targeting five new INDs for 2027, which underpins the potential future development of our next-generation antibody-based therapeutics. On the partnering front, we expect to continue pursuing preclinical partnerships to progress our preclinical development programs. This includes our expectation this year of partnering some of our early-stage assets as we continue progressing our ADC and MSAT portfolio in the coming years. As we leverage our focus R&D engine, we intend to continue our work to generate candidates where a partner may be the ideal choice to move them forward. For these assets, we will continue to seek attractive economics with upfront payments that help fund development of our in-house candidates. With that, I'd like to thank everyone for listening to our prepared remarks, and I'll turn the call over to the operator to begin the question and answer session. Operator? As a reminder, to ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by while we compile the Q&A roster. Our first question is from Stephen Willey with Stifel. Your line is open. Yeah, good afternoon. Thanks for taking the question. I guess just so I fully understand the Jazz amendment, I guess if I look at revenue this quarter, I think about, I don't know, about $34 million of that was either research support payments or drug supply payments from Jazz. I think about 80% of R&D were Zani-related clinical development costs. Should we just assume then that once the amendment closes at some point in 2Q, that those two things will no longer offset each other in the P&L? Yeah. I'll let Chris answer that. Go ahead, Chris. Yeah. No, you can. Yeah, thanks for the question. That's right. Post the closure of this transaction with Jazz, the revenues from Jazz from the expense reimbursement will go away, and also the direct expenses we're incurring and then being reimbursed from Jazz will also go away. It's just worth noting there will be a partial quarter in Q2 from the beginning of the quarter through to close. There will still be some revenue and expenses relating to that, but that will go away. It's just worth noting that revenue is recognized within the quarter, but then as is the expenses on the P&L. Then we keep that as accounts receivable on the balance sheet until it's reimbursed the following quarter. Okay, I get it. I know you've talked before about being able to potentially monetize some of the agreements from the portfolio that you have of legacy licensing agreements. How do you structurally go about this? Do you propose some kind of flat repurchasing cost to the original licensing party, or do you try to price this like an option and sell it to some third party? Would just be curious as to how you go about potentially realizing that strategy. Good question. Again, we, you know, we did look at a proposal last year to monetize a portion of the future milestones and royalties from all those legacy deals as a basket. Not entirely, but as a portion. We did that, you know, to have an additional you know, potential financing vehicle to the extent that we were, you know, later closing a partnership and collaboration on Zany than we were. You know, we didn't need to do that, we didn't execute that proposal. It was obviously at a higher cost of capital than we were able to get from the Jazz collaboration, there was no need to do it. I think, you know, this year in 2023, we, you know, we expect and hope that a number of those programs will progress. Once they do, we think that will throw off some additional milestone cash inflows to us, as well as, you know, progress a number of those programs to make the future milestones and royalties more valuable 'cause they'll be closer in time. It's something that, you know, after this year, if we can progress that pipeline, we may look at a similar structure or something that's a little bit different. But it is an ability for us to tap into a financing source should we choose to. We just weigh, you know, the amount of capital we could get, the cost of capital, and what we would use those funds for right now. Obviously, with a, you know, with a cash runway that's at least until 2026 and likely beyond, we don't see the need to draw on additional cost of capital right now, but it is always available to us. Okay, that's helpful. Thanks. Take the questions. You're welcome. Thank you, Steve. One moment for our next question. Our next question comes from Charles Zhu with Guggenheim Partners. Your line is open. Hey, good afternoon, everyone. Thanks for taking the questions and congrats on the progress. My first one, regarding zani-zo's clinical update in second half, any additional color around how we should be setting our expectations around that data set, particularly around distribution of histologies? Will we, for example, have additional line of sight for single agent data in your priority phase II indications such as non-small cell lung cancer or post-ENHERTU breast cancer? On a similarly related note, it sounds like the data will be from weekly dose cohorts. How much read-through will these data have to your other schedules that you may be evaluating with zani-zo? Thank you. Yeah, thanks for the question. I mean, obviously we have, you know, a tremendous amount of additional data that we've been able to accumulate since the cutoff for ESMO that was presented last year. In addition to following, you know, patients longer, we've got the QW dosing cohort finished. We've also enrolled additional patients on monotherapy at the 2.5 mgs per kg, including more patients in non-small cell lung cancer and more patients who are post ENHERTU in breast cancer. You know, we're still writing, you know, the abstract right now, Charles, so I can't say exactly what will be, what will be in it, but we're looking forward to provide, you know, as much context as we can for zani-zo. You know, in addition, we'll be, you know, closing that monotherapy arm and focusing on the combo studies that we're, you know, the other cohorts in non-small cell lung cancer and breast that we're looking forward to going ahead with. We're continuing to do some preclinical work around, you know, combinations, not with just PD-1, but TKIs and other, and other checkpoint inhibitor combinations beyond PD-1, 'cause I think there is some interest in looking at what might be possible by looking at CTLA-4 and even LAG-3 and others. There still is a tremendous preclinical work going on this year. I'm not sure, you know, what will be in the abstract that we submit at first, but I don't expect it to be our last disclosure on zani-zo. Got it. Sounds great, and thanks for that color. Maybe one follow-up, regarding some of those, combinations, especially with respect to combining zani-zo with the PD-1. Maybe something a bit more forward-looking. How are you thinking about enrollment criteria by PDL1 and/or HER2 status? Would patients need to be positive, I presume for both? Do you also intend on stratifying by level of positivity? Thanks. I mean, those are great questions. You know, you'll able to get some more information around that. You know, obviously, there's still a tremendous interest, as you can see from recent deal making in, you know, other options in the HER2 ADC space beyond T-DXd and T-DM1. We've been pretty clear our strategy with zani-zo has been to try to be the HER2 ADC of choice post T-DXd and try to give physicians, you know, a different mechanism on the antibody because it's, it is the biparatopic Zani backbone. We've tried to give KOLs a different payload, which is something that they've been requesting, and we'd like to give them the optionality of using Zani-Zo in combination with other agents as standard of care, in indications where it's applicable. That's how we arrived at right now, the post T-DXd space is defined in breast cancer and non- cell lung cancer. That's why we've, you know, let ourselves look at studying, you know, at least two cohorts in non-small cell lung cancer and at least two cohorts in breast cancer to get some clinical data to support, you know, what we think KOLs are asking for as another agent of choice in the HER2 ADC space. I think once you see the protocols on ClinicalTrials.gov, then you'll have a lot more information about the nature and the structure of those studies. Great. Thanks for taking the questions. You're welcome. Thank you. One moment for our next question. Our next question comes from Derek Archila with Wells Fargo. Your line is open. Hey, guys. Thanks for taking the questions and congrats on the progress. Just one question. Just wanna see if you have any thoughts or see any key learnings from mirvetuximab's recent MIRASOL data and how that might inform ZW-191's future development, either in ovarian or, you know, other potential tumor types. Thanks. No, great question. I guess, from our perspective, being in the biotech community, we always celebrate advances through innovation and obviously mirve is a step forward for a patient population who definitely needs a better standard of care. We're really excited for patients with the data we saw at MIRASOL. We're excited for the folks at ImmunoGen who really stuck with this for five, probably five or more difficult years in trying to bring this therapy to market. We feel happy for them. They've been vindicated with their desire to continue to move this forward when a number of years ago it may not have been the thing to look at doing. That's great from that perspective. Also in the biotech community, we also then try and do better than our peers, and that's what our goal is right now. I think from our perspective, there's a lot to learn from, you know, at least the initial patient population that's treatable with mirve. You know, I think looking at the low-grade ocular toxicities and how that's been perceived by regulators and also KOLs is kind of interesting for us, at least from a zani-zo perspective. I think going beyond that and looking at our own folate receptor alpha program, you know, we obviously have a very different strategy than mirve or the backup to mirve, which is being developed or some of the other agents, in that we're, you know, we're hoping to pursue the folate receptor alpha as a target, regardless of tumor type and regardless of expression levels in patients, which we think is really the next step beyond beyond where mirve has taken us. We're looking at a pretty broad patient population and seeing if we can find a particular type of ADC that we designed specifically with a broad patient population in mind, regardless of tumor type and regardless of expression levels, looking to see if we can find efficacy with it. That was the nature of our engineering for our ADC, and we're looking forward to putting that in the clinic next year and seeing if we can prove that out with clinical studies and prove out what we hope we designed from a protein engineering standpoint. I think we wanna go well beyond mirve and others in the folate receptor alpha targeted therapy space. Excellent. Thanks. You're welcome. Just to add that, sorry, just, you know, and from our perspective, you know, what we keep hearing from KOLs is that of significant interest, at least in the ovarian cancer space and some of beyond. We're really excited about, you know, our proprietary payload that we're testing on that ADC as well as the rest of the population that we might be able to provide a benefit for. One moment for our next question. Our next question comes from Brian Cheng with JP Morgan. Your line is open. Hey, Ken. good to hear from you. maybe just one quick question on BTC. Any updates on where you are in terms of the preparation for filing for BTC? you know, to the extent that you can you just give us some guidance on, you know, what could be the next update from our side that we could hear about the next potential steps in your BTC filing? No, great question. Obviously, you know, we've been working very carefully with both Jazz and BeiGene since our top-line data was announced in December last year, because it was, you know, it was quite exciting data, and really what we think might be transformative to the HER2 targeted therapy space in BTC. We've been working obviously with Jazz and BeiGene and discussing with regulators the pathway both in the U.S. and in potential markets outside the U.S. where we may be able to get an approval with this data set. You know, we haven't given guidance yet on timing of first filings. We will leave that to Jazz and BeiGene to discuss their filing strategies and timelines in their own jurisdictions. Obviously we've been working on supporting their potential regulatory filings, especially on the CMC module. Our work in CMC is complete, and we will ensure that that's not a rate limiting factor to filing, and we'll ensure that we're pre-approval inspection ready both in the U.S. and in foreign markets when necessary. I think we're ahead of the curve in that perspective, which is, you know, our main role right now with both Jazz and BeiGene. Obviously, you know, what's coming up is at ASCO we have an oral presentation with Dr. Pant, which we're really looking forward to sharing, you know, the full data set beyond the top-line data on zanidatamab's use, you know, as monotherapy in this patient population. We think it's, you know, potentially clinically meaningful improvement for this patient population which does not currently have an approved therapy. We're looking forward to sharing that information with KOLs and have been and will continue to share that information with the regulators. I think we'll leave the guidance on specific filing dates, but we're pretty excited. We also continue to enroll our phase II BTC study with first-line patients using zanidatamab in combination with gem/cis, and that continues to recruit. We're hoping that will inform, you know, the potential for zanidatamab in combination with gem/cis in an earlier patient population. I think as we've seen data come along from the use of PD-1 in gemcitabine in this patient population, there's certainly a thought that a HER2 target therapy for a patient with HER2 amplification is really the way to address the poor prognosis that goes along with that, with that genetic, you know, actionable biomarker. You know, that continues to go on. We haven't given guidance about, you know, when that might be fully recruited or what we might do beyond that. We'll let BeiGene and Jazz, you know, provide that guidance as well. Thanks, Ken. Thank you for the question. One moment for our next question. Our next question comes from Yigal Nochomovitz with Citi. Your line is open. Hi, team. This is Carly on for Yigal. Thanks for taking our questions. I'm just following up on a prior question related to the phase II strategy for zani-zo. I guess for lung, you've disclosed the PD-1 combo, but for breast, can you just talk about what combination partners you're considering, if you also plan to look at monotherapy in post in HER2 patients and just any feedback you've gotten from KOL on that. And then if you can also just clarify if you expect the phase IIs to be randomized studies, or single arms, that would be great as well. Thank you. Thanks. The second piece of that, you'll have to wait until you see the clinical protocols up on ClinicalTrials.gov. Obviously we've been, you know, in discussions with KOLs on the breast cancer cohorts. We're really interested in studying, you know, patients in a post-T-DXd environment after progression. We're also interested in studying patients in breast cancer who have, you know, lower levels of HER2 expression. We've been discussing with KOLs whether that should be done in a monotherapy setting to understand benefit of zani-zo or whether there are combination studies that we can look at. Obviously, we won't confirm that until you see the clinical protocols. In non-small cell lung cancer, it was easier with the prevalence of pembro being used as a standard of care. It was easier in the overexpressing population and, in the HER2 amplified populations who look at that as a natural combination to evaluate. Beyond that, in both those settings, there are other combinations which, you know, I don't think we'll be able to study within the current confines of our capital allocation for the phase IIs. You know, we've looked at and we will continue to look at preclinically, you know, combination with TKIs, which might be of interest, and also additional checkpoint inhibitor mechanisms beyond PD-1, which we think is something that might be interesting as well. I just don't think our capital allocation in phase II allows us to do that initially. It is something that we'll study preclinically and eventually with a partnership might allow us to study some additional combinations beyond the ones that we're currently gonna study in phase II. Okay, got it. That's very helpful. Thanks for taking the question. No, thanks for the question. One moment, please, for our next question. We have our last question from Akash Tewari with Jefferies. Your line is open. Hi, this is Phoebe on for Akash. Just regarding ZW49, can you comment on what ballpark you plan to spend in the program this year? What do you think of the competitive landscape for HER2 ADCs outside of ENHERTU? Thank you. On the first question, we won't talk about that ahead of time, but obviously on a quarterly basis when we file our financial statements, including Q-one, which you'll see, you'll see how spending is allocated between zani-zo and zani and the early-stage pipeline. I think as we go through the year on a quarterly basis, you'll be able to see how the actual spending is has been made. You'll answer that in a retrospective manner. I think on the HER2 ADC space, I think, you know, we've seen some additional business development interests and other folks moving ahead on investments, and I think that's because they're probably hearing the same messages that we are from KOLs, is that they're looking for additional options as ADC formats in their HER2-targeted therapy space. I think that's pushing a lot of folks to look at how they would compete strategically in that segment. We've been very clear about our strategy of trying to find a way to fit into the post-T-DXd space. We think it's very attractive from an economic perspective, and we think it's an area that we can, with zani-zo, provide some optionality for physicians to follow T-DXd with an antibody that's not Traz, with a payload that's not DXd, with a mechanism that's quite different because of the biparatopic nature of binding with zani-zo. Also the optionality of using it in combination with other standards of care because the tolerability profile is, from what we've seen clinically, the best of any HER2 ADC that's been studied clinically to date and released data. We've been very clear about where we would like to compete in that space, and we've been clear about the phase II studies that we've designed that we expect to initiate this year. We'll provide data to show that we can compete in that space, we hope that data is, you know, overwhelming enough to allow us to invest further and to find a partner on an ex-U.S. basis who wants to join us in that to find a regulatory pathway for zani-zo to be the next choice ADC in a T-DXd environment. I think we're quite excited that there's room in that space to compete, provide physicians with something more than they can currently get from T-DXd and T-DM1, and that zani-zo might be well-positioned in combination to play a major role in that. That's why we're strategically allocating some capital along with a substantial amount of capital in our 5x5 strategy in our early stage portfolio. Great. Thank you. You're welcome. Thank you. I'm showing no further questions at this time. I would like to turn it back over to Kenneth Galbraith for any closing remarks. Great. Thank you, operator. Thank you for attending our Q1 earnings and business update call. As you can hopefully tell, we're pretty excited about 2023 and the progress we expect to make in the entire pipeline. We're excited about where we are with zanidatamab with our partners Jazz and BeiGene. We think we have a clear path for some additional phase II clinical studies in zani-zo. I think our two next agents to go to the clinic are on track in 2024 to be INDs, both the folate receptor alpha and mesothelin 2+1 T-cell engager. We're thinking now about what, you know, what's gonna be next into the clinic beyond those two and hope to have some updates for you soon on that. In addition, we're hopefully making some progress with some of the legacy licensing platform deals we have, which will provide some cash flows and also some additional value that we can potentially monetize in the future if we have some additional need for some capital. We're excited about that. The team's working very hard, and we look forward to presenting some additional progress for you next up at ASCO, and we hope you have the ability to attend or listen to the oral presentation from Dr. Pant in the full BTC data, as well as the update from BeiGene on looking at the use of zanidatamab and docetaxel in first-line breast cancer patients, which we think is going to be really encouraging for future indications with zanidatamab. Thank you very much for your attention, and I look forward to updating you again over the course of the quarter and at the end of Q2 as well. This concludes today's conference call. Thank you for participating. You may now disconnect.